Ira Miller

Ira Miller

Auto-generated profile, based on publicly available information

Ira Miller

The Ohio State University 2 Medical Scientist Training Program, College of Medicine Columbus, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Clinical Biochemistry
Verified
Journal Article
Closed access
IMIra D Miller
Ira D Miller
MKMindy C. Kohlhagen
Mindy C. Kohlhagen
PLPaula M. Ladwig
Paula M. Ladwig
SDSurendra Dasari
Surendra Dasari
SKShaji Kumar
Shaji Kumar
DMDavid L. Murray
David L. Murray

1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Lysine-specific demethylase 1 (LSD1), encoded by the gene KDM1A, is overexpressed and correlates with poor patient prognosis in Ewing sarcoma. LSD1 and the pathognomonic fusion oncoprotein, EWSR1::FLI1, colocalize throughout the genome, suggesting that LSD1 is a critical co-regulator driving the progression of Ewing sarcoma. However, therapeutic targeting of LSD1 by competitive and noncompetitive inhibitors has yielded mixed results. Irreversible, enzymatic inhibition seems ineffective, but reversible noncompetitive inhibition has predominant off-target mechanisms, leaving open the question of LSD1 function in Ewing sarcoma. In this study, we take a robust approach through multiple methods of depletion in multiple Ewing sarcoma cell lines to define enzymatic and nonenzymatic contributions of LSD1 to transcriptional regulation. We define a core set of 22 genes that are commonly repressed by LSD1 in all cell lines and that repression of these genes downregulates synapse functioning and e-cadherin target genes. Derepression of these genes with LSD1 loss is an early and sustained genotype in all cell lines tested. We further define distinct gene sets in each cell line that are regulated by enzymatic and nonenzymatic LSD1 activity and find repression of e-cadherin target genes to be nonenzymatically regulated. This finding supports the growing body of evidence that in addition to their canonical catalytic activity, chromatin regulatory enzymes serve essential noncanonical roles as well. Furthermore, we uncovered evidence through use of the irreversible inhibitor OG-L002 that 2D cytotoxicity and proliferation assays may be insufficient to determine Ewing sarcoma response to LSD1 inhibition. Significance: In this study, we address a long-standing question in the field surrounding LSD1 and define the distinct enzymatic and nonenzymatic functions of LSD1 in Ewing sarcoma. In doing so, we have created a robust data set using genetic and pharmacologic techniques in multiple models to thoroughly characterize LSD1 function in Ewing sarcoma cell lines.

18 March 2026
Verified
Other
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Principal Component Analysis of OG-L002 treatment in A673, CHP-100, and TTC-466 cells.

18 March 2026
Verified
Other
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
LSD1 functions predominantly nonenzymatically in A673. A, Schematic of KO and viral transduction of LSD1wt and LSD1ed harboring K661Q and A539E mutations. B, AlphaFold structure prediction of the enzymatic pocket of LSD1 with K661Q and A539E mutations highlighted. C, Western blot validating rescue of LSD1 protein with the proper 2xHA-tag, and qRT-PCR fold change of regions spanning the exon 2 to 3 junction and within the 3′UTR. UTR, untranslated region. D, Principal component analysis (PCA) of A673 rescue samples comparing PC2 vs. PC3. E, Table of DEGs between the endogenous LSD1 (LSD1endo), LSD1wt, and LSD1ed compared with LSD1KO. F, Overlap of genes downregulated by expression of LSD1wt and LSD1ed. Genes common between LSD1wt and LSD1ed are defined to be nonenzymatic gene targets and are circled in purple. Genes down regulated by LSD1wt but unaffected by LSD1ed are defined to be enzymatically regulated genes and are circled in red. Pathway analysis on both enzymatic and nonenzymatic gene sets ranked by gene ratio in A673 based on (G) MSigDB curated and (H) Gene Ontology Biological Processes (GOBP) databases. [A, Created in BioRender. Dreher, R. (2026) https://BioRender.com/06wisji.]

18 March 2026
Verified
Other
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Derepression of CDH1 target genes is early and sustained after LSD1 degradation. A, A673 (B) CHP-100 and (C) TTC-466 representative Western blots and densitometry quantification of LSD1 degradation after DMSO and 800 nmol/L of UM171 for 6 and 24 hours. Asterisks represent the significance of the comparison (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001), D–F, Overlaps of genes commonly upregulated between KO and UM171 at 6, 24, and 96 hours in all three cell lines. A table summarizing genes commonly (G) upregulated and (H) downregulated between KO and UM171 at 6, 24, and 96 hours and all three time points in each of the three cell lines. Representative pathway analysis of A673 ranked by gene ratio between KO and UM171 at 6, 24, and 96 hours using (I) MSigDB curated and (J) Gene Ontology Biological Processes (GOBP) databases.

18 March 2026
Verified
Other
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Principal Component Analysis of differential gene expression for rescue experiments in A673 and CHP-100 cells